201 related articles for article (PubMed ID: 29658114)
1. Proton pump inhibitor use and cancer mortality.
Tvingsholm SA; Dehlendorff C; Østerlind K; Friis S; Jäättelä M
Int J Cancer; 2018 Sep; 143(6):1315-1326. PubMed ID: 29658114
[TBL] [Abstract][Full Text] [Related]
2. Use of proton pump inhibitors and mortality among Icelandic patients with prostate cancer.
Hálfdánarson ÓÖ; Pottegård A; Lund SH; Ogmundsdottir MH; Ogmundsdottir HM; Zoega H
Basic Clin Pharmacol Toxicol; 2020 Jun; 126(6):484-491. PubMed ID: 31872571
[TBL] [Abstract][Full Text] [Related]
3. Proton pump inhibitors and risk of all-cause and cause-specific mortality: A cohort study.
Brown JP; Tazare JR; Williamson E; Mansfield KE; Evans SJ; Tomlinson LA; Bhaskaran K; Smeeth L; Wing K; Douglas IJ
Br J Clin Pharmacol; 2021 Aug; 87(8):3150-3161. PubMed ID: 33393677
[TBL] [Abstract][Full Text] [Related]
4. Proton Pump Inhibitor Use and the Risk of Chronic Kidney Disease.
Lazarus B; Chen Y; Wilson FP; Sang Y; Chang AR; Coresh J; Grams ME
JAMA Intern Med; 2016 Feb; 176(2):238-46. PubMed ID: 26752337
[TBL] [Abstract][Full Text] [Related]
5. Increased mortality in patients with hematologic malignancies treated with proton pump inhibitors: a nationwide cohort study.
Vilmar A; Dehlendorff C; Friis S; Jäättelä M; Tvingsholm S; Frederiksen H
Leuk Lymphoma; 2023; 64(8):1451-1457. PubMed ID: 37293759
[TBL] [Abstract][Full Text] [Related]
6. Risk of death among users of Proton Pump Inhibitors: a longitudinal observational cohort study of United States veterans.
Xie Y; Bowe B; Li T; Xian H; Yan Y; Al-Aly Z
BMJ Open; 2017 Jul; 7(6):e015735. PubMed ID: 28676480
[TBL] [Abstract][Full Text] [Related]
7. Use of Acid-Suppressant Medications After Diagnosis Increases Mortality in a Subset of Gastrointestinal Cancer Patients.
Ayyagari S; Tan MC; Liu Y; El-Serag HB; Thrift AP
Dig Dis Sci; 2020 Sep; 65(9):2691-2699. PubMed ID: 31802383
[TBL] [Abstract][Full Text] [Related]
8. Maintenance therapy with proton pump inhibitors and risk of gastric cancer: a nationwide population-based cohort study in Sweden.
Brusselaers N; Wahlin K; Engstrand L; Lagergren J
BMJ Open; 2017 Oct; 7(10):e017739. PubMed ID: 29084798
[TBL] [Abstract][Full Text] [Related]
9. Maintenance Proton Pump Inhibitor Use Associated with Increased All-Cause and Cause-Specific Mortality in Sweden.
Ngwenya S; Simin J; Brusselaers N
Dig Dis Sci; 2023 Jun; 68(6):2252-2263. PubMed ID: 36629968
[TBL] [Abstract][Full Text] [Related]
10. Use of proton pump inhibitors and risk of pancreatic cancer.
Hicks B; Friis S; Pottegård A
Pharmacoepidemiol Drug Saf; 2018 Aug; 27(8):926-930. PubMed ID: 29923251
[TBL] [Abstract][Full Text] [Related]
11. Lack of Association Between Proton Pump Inhibitor Use and Cognitive Decline.
Wod M; Hallas J; Andersen K; García Rodríguez LA; Christensen K; Gaist D
Clin Gastroenterol Hepatol; 2018 May; 16(5):681-689. PubMed ID: 29391266
[TBL] [Abstract][Full Text] [Related]
12. Long-term use of proton pump inhibitors, dose-response relationship and associated risk of ischemic stroke and myocardial infarction.
Sehested TSG; Gerds TA; Fosbøl EL; Hansen PW; Charlot MG; Carlson N; Hlatky MA; Torp-Pedersen C; Gislason GH
J Intern Med; 2018 Mar; 283(3):268-281. PubMed ID: 29024109
[TBL] [Abstract][Full Text] [Related]
13. Proton pump inhibitors and the risk of acute kidney injury in cancer patients receiving immune checkpoint inhibitors: A Danish population-based cohort study.
Munch PV; Nørgaard M; Heide-Jørgensen U; Jensen SK; Birn H; Christiansen CF
Int J Cancer; 2024 Apr; 154(7):1164-1173. PubMed ID: 37983738
[TBL] [Abstract][Full Text] [Related]
14. Outcomes with concurrent use of clopidogrel and proton-pump inhibitors: a cohort study.
Ray WA; Murray KT; Griffin MR; Chung CP; Smalley WE; Hall K; Daugherty JR; Kaltenbach LA; Stein CM
Ann Intern Med; 2010 Mar; 152(6):337-45. PubMed ID: 20231564
[TBL] [Abstract][Full Text] [Related]
15. Proton pump inhibitors and survival in patients with colorectal cancer: a Swedish population-based cohort study.
Wang X; Liu Q; Halfdanarson ÓÖ; Zoega H; Sadr-Azodi O; Engstrand L; Fall K; Brusselaers N
Br J Cancer; 2021 Sep; 125(6):893-900. PubMed ID: 34253872
[TBL] [Abstract][Full Text] [Related]
16. No Increase in Risk of Acute Myocardial Infarction in Privately Insured Adults Prescribed Proton Pump Inhibitors vs Histamine-2 Receptor Antagonists (2002-2014).
Landi SN; Sandler RS; Pate V; Lund JL
Gastroenterology; 2018 Mar; 154(4):861-873.e6. PubMed ID: 29122546
[TBL] [Abstract][Full Text] [Related]
17. Proton pump inhibitors and risk of gastric cancer: a population-based cohort study.
Poulsen AH; Christensen S; McLaughlin JK; Thomsen RW; Sørensen HT; Olsen JH; Friis S
Br J Cancer; 2009 May; 100(9):1503-7. PubMed ID: 19352380
[TBL] [Abstract][Full Text] [Related]
18. Association Between Proton Pump Inhibitor Use and Risk of Asthma in Children.
Wang YH; Wintzell V; Ludvigsson JF; Svanström H; Pasternak B
JAMA Pediatr; 2021 Apr; 175(4):394-403. PubMed ID: 33555324
[TBL] [Abstract][Full Text] [Related]
19. Comparative risk of Clostridium difficile infection between proton pump inhibitors and histamine-2 receptor antagonists: A 15-year hospital cohort study using a common data model.
Seo SI; You SC; Park CH; Kim TJ; Ko YS; Kim Y; Yoo JJ; Kim J; Shin WG
J Gastroenterol Hepatol; 2020 Aug; 35(8):1325-1330. PubMed ID: 31970824
[TBL] [Abstract][Full Text] [Related]
20. Ranitidine and Risk of Bladder and Kidney Cancer: A Population-Based Cohort Study.
Nørgaard M; Andersen IT; Heide-Jørgensen U; Erichsen R; Rees JR; Karagas MR; Sørensen HT
Cancer Epidemiol Biomarkers Prev; 2022 Jan; 31(1):45-50. PubMed ID: 34649959
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
